Equity Research, Broker Reports, and media content on Diurnal Group

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Diurnal Group
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard
  • 20 Jan 20
SP Angel Healthcare Conditions

Open Orphan (ORPH.L): Completion of merger with hVIVO | Diurnal Group plc (DNL.L): Business and trading update | IQ-AI (IQAI.L): Korean regulatory clearance for StoneChecker® software

Companies: ORPH DNL IQAI

  • 20 Jan 20
SP Angel Healthcare Conditions

Open Orphan (ORPH.L): Completion of merger with hVIVO | Diurnal Group plc (DNL.L): Business and trading update | IQ-AI (IQAI.L): Korean regulatory clearance for StoneChecker® software

Companies: ORPH DNL IQAI

  • 10 Jan 20
THE MONTHLY January 2020

The Office for National Statistics (ONS) is due to publish its most up-to-date survey on share ownership in mid-January, which identifies the beneficial owners and decision- makers of the stock market. Hardman & Co has worked together with the share analysis service, Argus Vickers, to jointly produce its own survey, which anticipates the conclusions of the ONS survey but goes into much greater detail. Our work does not use a sample of 200 quoted companies as the ONS historically has, but rather includes everyUK quoted company. The ONS samples share registers every two years; our study uses six-monthly data points. Our survey also extends to shareholders on NEX; the ONS does not.

Companies: AVO AGY ARBB BUR CMH CLIG DNL FLTA GDR MCL NSF PCA PIN PHP RECI RMDL SCE SIXH SHED VTA

  • 10 Jan 20
THE MONTHLY January 2020

The Office for National Statistics (ONS) is due to publish its most up-to-date survey on share ownership in mid-January, which identifies the beneficial owners and decision- makers of the stock market. Hardman & Co has worked together with the share analysis service, Argus Vickers, to jointly produce its own survey, which anticipates the conclusions of the ONS survey but goes into much greater detail. Our work does not use a sample of 200 quoted companies as the ONS historically has, but rather includes everyUK quoted company. The ONS samples share registers every two years; our study uses six-monthly data points. Our survey also extends to shareholders on NEX; the ONS does not.

Companies: AVO AGY ARBB BUR CMH CLIG DNL FLTA GDR MCL NSF PCA PIN PHP RECI RMDL SCE SIXH SHED VTA

  • 16 Dec 19
SP Angel Healthcare Conditions

Microsaic (MSYS.L): Collaboration with the Centre for Process Innovation (CPI) | Diurnal (DNL.L): Chronocort® MAA submitted for EU approval

Companies: Microsaic Systems Diurnal Group

  • 16 Dec 19
SP Angel Healthcare Conditions

Microsaic (MSYS.L): Collaboration with the Centre for Process Innovation (CPI) | Diurnal (DNL.L): Chronocort® MAA submitted for EU approval

Companies: Microsaic Systems Diurnal Group

  • 02 Dec 19
SP Angel Healthcare Conditions

Creo Medical Group plc (CREO.L): Fundraising of over £43.0m | Fusion Antibodies (FAB.L): Half year results | Diurnal Group plc (DNL.L): Alkindi New Drug Application Submitted to FDA | Yourgene Health (YGEN.L): Results for the 6-months ended 30 September 2019

Companies: CREO FAB DNL YGEN

  • 02 Dec 19
SP Angel Healthcare Conditions

Creo Medical Group plc (CREO.L): Fundraising of over £43.0m | Fusion Antibodies (FAB.L): Half year results | Diurnal Group plc (DNL.L): Alkindi New Drug Application Submitted to FDA | Yourgene Health (YGEN.L): Results for the 6-months ended 30 September 2019

Companies: CREO FAB DNL YGEN

  • 26 Nov 19
Successful DITEST Phase I trial outcome

Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products, Alkindi and Chronocort, are in late-stage clinical trials, with Alkindi already licensed in Europe. With the successful outcome of the Phase I trial with DITEST, an oral testosterone replacement formulation, DNL is building on its vision of becoming a leading speciality endocrinology company. The study showed that DITEST was safe, well tolerated and well absorbed in men affected by hypogonadism. DNL will engage with the regulators for the next trial stage, which is likely to be run with a partner.

Companies: Diurnal Group
  • 26 Nov 19
Successful DITEST Phase I trial outcome

Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products, Alkindi and Chronocort, are in late-stage clinical trials, with Alkindi already licensed in Europe. With the successful outcome of the Phase I trial with DITEST, an oral testosterone replacement formulation, DNL is building on its vision of becoming a leading speciality endocrinology company. The study showed that DITEST was safe, well tolerated and well absorbed in men affected by hypogonadism. DNL will engage with the regulators for the next trial stage, which is likely to be run with a partner.

Companies: Diurnal Group
  • 22 Nov 19
Small Cap Feast

The FT reports that World Chess has announced plans for a novel “hybrid” IPO where it will first issue a digital token ahead of an AIM float The Pebble Group, a provider of products, services and technology to the global promotional products industry, announces its intention to seek admission of its shares to trading on the AIM market of the London Stock Exchange, which is expected to take place in early December 2019.The Group delivered revenue of £99.8m in the year ended 31 December 2018.No mention of bottom line and a suggestion that funds raised would provide an exit to private equity shareholders and the repayment of debt. Offer TBA. Longboat Energy raising £10m. Expected admission November 2019. The company has been established by the former management team of Faroe Petroleum to create a new full-cycle North Sea oil and gas company .The strategy to achieve this will initially be through the acquisition of assets where the management team can add value through subsurface and operational improvements, follow-up deal opportunities and nearfield exploration; and by value creation through the drill bit. Sapo PLC - Seeks to invest in the developing market for rural broadband in the UK. Due 2 Dec. Taseko Mines - North American focused copper producer and developer, seeking a London Listing. No capital raise. Due 22 Dec SDIC Power - “potential intention to float”. Proposed GDR listing. Leading power generation company in China, with a diversified portfolio of projects across hydropower, coal-fired power, wind power and solar power. Offer TBA. Octopus Renewables - Seeking raise of up to £250m. Will seek to provide investors with an attractive and sustainable level of income returns, with an element of capital growth by investing in a geographically and technologically diversified spread of renewable energy assets—Due 10 Dec

Companies: BRK DNL POS YEW SML AAU KCT LVCG CCS HAYD

  • 22 Nov 19
Small Cap Feast

The FT reports that World Chess has announced plans for a novel “hybrid” IPO where it will first issue a digital token ahead of an AIM float The Pebble Group, a provider of products, services and technology to the global promotional products industry, announces its intention to seek admission of its shares to trading on the AIM market of the London Stock Exchange, which is expected to take place in early December 2019.The Group delivered revenue of £99.8m in the year ended 31 December 2018.No mention of bottom line and a suggestion that funds raised would provide an exit to private equity shareholders and the repayment of debt. Offer TBA. Longboat Energy raising £10m. Expected admission November 2019. The company has been established by the former management team of Faroe Petroleum to create a new full-cycle North Sea oil and gas company .The strategy to achieve this will initially be through the acquisition of assets where the management team can add value through subsurface and operational improvements, follow-up deal opportunities and nearfield exploration; and by value creation through the drill bit. Sapo PLC - Seeks to invest in the developing market for rural broadband in the UK. Due 2 Dec. Taseko Mines - North American focused copper producer and developer, seeking a London Listing. No capital raise. Due 22 Dec SDIC Power - “potential intention to float”. Proposed GDR listing. Leading power generation company in China, with a diversified portfolio of projects across hydropower, coal-fired power, wind power and solar power. Offer TBA. Octopus Renewables - Seeking raise of up to £250m. Will seek to provide investors with an attractive and sustainable level of income returns, with an element of capital growth by investing in a geographically and technologically diversified spread of renewable energy assets—Due 10 Dec

Companies: BRK DNL POS YEW SML AAU KCT LVCG CCS HAYD

  • 20 Nov 19
Small Cap Feast

The Pebble Group, a provider of products, services and technology to the global promotional products industry, announces its intention to seek admission of its shares to trading on the AIM market of the London Stock Exchange, which is expected to take place in early December 2019.The Group delivered revenue of £99.8m in the year ended 31 December 2018.No mention of bottom line and a suggestion that funds raised would provide an exit to private equity shareholders and the repayment of debt. Offer TBA. Longboat Energy raising £10m. Expected admission November 2019. The company has been established by the former management team of Faroe Petroleum to create a new full-cycle North Sea oil and gas company .The strategy to achieve this will initially be through the acquisition of assets where the management team can add value through subsurface and operational improvements, follow-up deal opportunities and nearfield exploration; and by value creation through the drill bit.

Companies: FOG TPFG DNL FIF BREE GRL AVO INFA EMH

  • 20 Nov 19
Small Cap Feast

The Pebble Group, a provider of products, services and technology to the global promotional products industry, announces its intention to seek admission of its shares to trading on the AIM market of the London Stock Exchange, which is expected to take place in early December 2019.The Group delivered revenue of £99.8m in the year ended 31 December 2018.No mention of bottom line and a suggestion that funds raised would provide an exit to private equity shareholders and the repayment of debt. Offer TBA. Longboat Energy raising £10m. Expected admission November 2019. The company has been established by the former management team of Faroe Petroleum to create a new full-cycle North Sea oil and gas company .The strategy to achieve this will initially be through the acquisition of assets where the management team can add value through subsurface and operational improvements, follow-up deal opportunities and nearfield exploration; and by value creation through the drill bit.

Companies: FOG TPFG DNL FIF BREE GRL AVO INFA EMH

  • 05 Nov 19
Approaching a number of near-term milestones

Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term ‘Adrenal Franchise’. The first product, Alkindi®, is being rolled out through key EU markets, and sales have exceeded the £1.0m mark. Despite unexpected Phase III results, positive feedback from the EMA has cleared the path for regulatory submission of Chronocort for adult CAH in Europe before the end of 2019. It has also allowed DNL to revise the primary endpoint in the protocol for the US Chronocort Phase III trial.

Companies: Diurnal Group
  • 05 Nov 19
Approaching a number of near-term milestones

Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term ‘Adrenal Franchise’. The first product, Alkindi®, is being rolled out through key EU markets, and sales have exceeded the £1.0m mark. Despite unexpected Phase III results, positive feedback from the EMA has cleared the path for regulatory submission of Chronocort for adult CAH in Europe before the end of 2019. It has also allowed DNL to revise the primary endpoint in the protocol for the US Chronocort Phase III trial.

Companies: Diurnal Group
  • 04 Nov 19
THE MONTHLY November 2019

The trade-off in the risk/reward for gold and gold mining equities is improving, as central banks push the current iteration of the post-World War II Bretton Woods financial order towards its limits.

Companies: AVO AJB AGY ARBB BUR CLIG DNL DPP FLTA GTLY GDR MCL MUR NSF PCA PIN SRE PHP RE/ RECI RMDL STX SCE TON SHED VTA W7L

  • 04 Nov 19
THE MONTHLY November 2019

The trade-off in the risk/reward for gold and gold mining equities is improving, as central banks push the current iteration of the post-World War II Bretton Woods financial order towards its limits.

Companies: AVO AJB AGY ARBB BUR CLIG DNL DPP FLTA GTLY GDR MCL MUR NSF PCA PIN SRE PHP RE/ RECI RMDL STX SCE TON SHED VTA W7L

  • 03 Oct 19
THE MONTHLY October 2019

Since their privatisation in 1989, the 10 water companies have faced a periodic review every five years; it is undertaken by Ofwat, and prescribes customer prices, along with the investment requirements. As part of the ongoing review, PR19, Ofwat will publish its Final Determination numbers on 11 December 2019; they will apply as from April 2020, although water companies do have the option to seek a reference to the CMA.

Companies: AJB AGY ARBB CLIG DNL DPP FLTA GTLY GDR KOOV MCL MUR NSF PCA PIN PHP RE/ RECI RMDL STX SCE SIXH TON SHED VTA W7L

  • 03 Oct 19
THE MONTHLY October 2019

Since their privatisation in 1989, the 10 water companies have faced a periodic review every five years; it is undertaken by Ofwat, and prescribes customer prices, along with the investment requirements. As part of the ongoing review, PR19, Ofwat will publish its Final Determination numbers on 11 December 2019; they will apply as from April 2020, although water companies do have the option to seek a reference to the CMA.

Companies: AJB AGY ARBB CLIG DNL DPP FLTA GTLY GDR KOOV MCL MUR NSF PCA PIN PHP RE/ RECI RMDL STX SCE SIXH TON SHED VTA W7L

  • 26 Sep 19
Well on the way to becoming a major player in endocrine diseases

Diurnal is a rare breed amongst British smaller companies in the life sciences sector, and indeed globally, in that within a little over two years since listing it has achieved commercialisation in Europe of an authorised medicine for a rare paediatric condition. From within its rich pipeline of endocrine focussed candidates, Diurnal has also completed a pivotal Phase 3 study in another late stage candidate with a regulatory pathway defined suggesting that a second product could be generating revenues by the end of 2021. The Company this week reported FY June 2019 results ahead of expectations.

Companies: Diurnal Group
  • 26 Sep 19
Well on the way to becoming a major player in endocrine diseases

Diurnal is a rare breed amongst British smaller companies in the life sciences sector, and indeed globally, in that within a little over two years since listing it has achieved commercialisation in Europe of an authorised medicine for a rare paediatric condition. From within its rich pipeline of endocrine focussed candidates, Diurnal has also completed a pivotal Phase 3 study in another late stage candidate with a regulatory pathway defined suggesting that a second product could be generating revenues by the end of 2021. The Company this week reported FY June 2019 results ahead of expectations.

Companies: Diurnal Group
  • 24 Sep 19
Small Cap Feast

AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019

Companies: DNL MTPH SYM ANCR SLN MOSB ALM GTC JTWO WKP

  • 24 Sep 19
Small Cap Feast

AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019

Companies: DNL MTPH SYM ANCR SLN MOSB ALM GTC JTWO WKP

  • 03 Sep 19
THE MONTHLY September 2019

The challenges associated with value creation drive all investors. Any investment professional is eager to make their mark by picking organisations that are able to deliver superior returns. Increasingly investors look into how organisations are governed and how effective the top decision-making bodies of organisations really are. In this white paper, we shed light on research findings and reveal the seven hallmarks of effective boards. The seven hallmarks are proven to create more effective boards and are set to be the next lever in the value creation process. Better Boards has created advanced board evaluation tools designed to motivate and inspire and above all, contribute to superior value creation.

Companies: AVO AJB AGY CLIG DNL DPP FLTA GTLY GDR KOOV MUR NSF OXB PCA PHP RE/ RMDL STX SCE TRX TON SHED VTA W7L

  • 03 Sep 19
THE MONTHLY September 2019

The challenges associated with value creation drive all investors. Any investment professional is eager to make their mark by picking organisations that are able to deliver superior returns. Increasingly investors look into how organisations are governed and how effective the top decision-making bodies of organisations really are. In this white paper, we shed light on research findings and reveal the seven hallmarks of effective boards. The seven hallmarks are proven to create more effective boards and are set to be the next lever in the value creation process. Better Boards has created advanced board evaluation tools designed to motivate and inspire and above all, contribute to superior value creation.

Companies: AVO AJB AGY CLIG DNL DPP FLTA GTLY GDR KOOV MUR NSF OXB PCA PHP RE/ RMDL STX SCE TRX TON SHED VTA W7L

  • 01 Aug 19
THE MONTHLY August 2019

The introduction of IFRS 2 in 2004 generated considerable debate about the best approach for handling ‘share-based payments’ (SBP). While it is clearly a cost to shareholders, which should be included in the statutory reporting lines through the P&L account, the question arose as to whetherit should be part of our underlying EBIT calculation.

Companies: AVO AJB AGY ARBB CLIG DNL DPP FLTA GTLY GDR KOOV MCL MUR NSF OXB PCA PHP RE/ REDX RMDL STX SCE TRX TON SHED VAL VTA W7L

  • 01 Aug 19
THE MONTHLY August 2019

The introduction of IFRS 2 in 2004 generated considerable debate about the best approach for handling ‘share-based payments’ (SBP). While it is clearly a cost to shareholders, which should be included in the statutory reporting lines through the P&L account, the question arose as to whetherit should be part of our underlying EBIT calculation.

Companies: AVO AJB AGY ARBB CLIG DNL DPP FLTA GTLY GDR KOOV MCL MUR NSF OXB PCA PHP RE/ REDX RMDL STX SCE TRX TON SHED VAL VTA W7L

  • 02 Jul 19
THE MONTHLY July 2019

When advisers first start looking at business relief (BR) products, there is much to take in: the rules governing such products; the investment strategies being used; and what the investment risk is. It is easy to lose sight of the fact that, for non-AIM products, the investment is being made directly into a company or partnership, rather than a fund. It is, therefore, essential that governance is part of the diligence process.

Companies: AVO AJB AGY ARBB CLIG DNL DPP FLTA GTLY KOOV LWRF MCL MUR NSF OXB PCA PHP RE/ REDX RMDL STX SIXH TRX TON SHED VAL VTA W7L

  • 02 Jul 19
THE MONTHLY July 2019

When advisers first start looking at business relief (BR) products, there is much to take in: the rules governing such products; the investment strategies being used; and what the investment risk is. It is easy to lose sight of the fact that, for non-AIM products, the investment is being made directly into a company or partnership, rather than a fund. It is, therefore, essential that governance is part of the diligence process.

Companies: AVO AJB AGY ARBB CLIG DNL DPP FLTA GTLY KOOV LWRF MCL MUR NSF OXB PCA PHP RE/ REDX RMDL STX SIXH TRX TON SHED VAL VTA W7L

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Diurnal Group. We currently have 70 research reports from 4 professional analysts.

Open
N/A
Range Today
N/A
52 Week
23.3/46.0p
Daily Volume
N/A
# Shares
86.7m
Daily Liquidity
(0.03%)
Pension Liability
£0m
Enterprise Value
£15.9m
Market Cap
£24.7m
Latest PE (hist)
Div Yield

Latest News/RNS

(more news)
Date Source Announcement
20Jan20 07:00 RNS Business and trading update
13Jan20 07:00 RNS Holding(s) in Company
13Jan20 07:00 RNS Notice of Interim Results
10Jan20 15:45 RNS Director Dealings and Issue of Equity
10Jan20 15:44 RNS Issue of Long-Term Incentive Plan awards
16Dec19 11:46 RNS Director Dealings
16Dec19 07:00 RNS Chronocort MAA Submitted in Europe
Get free RNS email alerts

  • Frequency of research reports

     

  • Research reports on

    Diurnal Group

  • Providers covering

    Diurnal Group

  • 23 Jan 20
Positive 17-month trading update

Avacta released a positive trading update for the 17 months to 31 December, with revenues and cash both £0.4m higher than we expected (8% and 5% higher, respectively). This was driven by customer Affimer evaluations and services relating to its partnership programmes, which in turn drove year-end cash. Avacta continues to build value into the business by progressing its proprietary therapeutics assets and partnered programmes, which now extend to four (Moderna Therapeutics, LG Chem, ADC Therapeutics and Daewoong Pharmaceutical). Its focus remains on taking its first pre|CISION pro-drug (pro-doxorubicin) into the clinic in mid-2020, with first data expected by year-end. We maintain our target price of 76p.

Companies: Avacta Group
  • 22 Jan 20
Deltex Medical*

Pre-close trading update

Companies: Deltex Medical Group
  • 21 Oct 19
Quarterly Research Outlook Autumn 2019

Following continued delays of a Brexit agreement, few sectors within the UK market have remained attractive to investors despite low valuations. One sector which has continued to outperform despite the political drama has been the UK video gaming sector (henceforth UK gaming), which we are fans of. We believe a combination of sector-leading growth, strong cash conversion and timely cyclical positioning support our positive view on the UK video gaming sector.

Companies: ABBY AMS ANX ARS ATYM AVON BLVN PIER BUR CGS CAML CDM CSRT TIDE CYAN DTG DEMG ELM EMR FPO FDEV GTLY GENL GHH GRI GEEC GKP HMI HAYD HEAD HILS HTG HUR IBPO IOG INDI JHD JOG KAPE KEYS KWS KCT KGH LAM LIT LOK MACF MANO MOD OXIG PCA PANR APP SRE PHC PMO RBW RMM RBGP REDD RSW RNO ROR SUS SCPA SEN SHG SOLG SOM SUMO TM17 INCE TWD TRAK TRI VNET VTC ZOO ZTF

  • 13 Jan 20
Shield Therapeutics - Feraccru out-licensed in China

Shield Therapeutics has kick-started 2020 by securing an out-licensing deal in China for its primary asset, Feraccru/Accrufer. The exclusive deal with China-based Beijing Aosaikang Pharmaceutical (ASK Pharm) covers China, Hong Kong, Macau and Taiwan. ASK Pharm will complete any required clinical trials in China and file the marketing authorisation for the treatment of iron deficiency in all territories covered by the deal; we forecast China launch in 2023. Shield will receive an upfront licensing payment of $11.4m which, importantly, has extended the cash runway into 2021. The next key inflection point is a US partnering deal, which we assume will occur in the next 12 months; upfront payments from a deal will enhance Shield’s balance sheet further. We value Shield at £346.8m

Companies: Shield Therapeutics
  • 21 Jan 20
LIBERUM: Sensyne Health* - On-track to deliver 2020 targets

Sensyne reported H1 2020 results this morning which were in-line with our forecasts. More importantly the company remains on-track to meet our full year revenue estimate and has plenty of headroom to meet our net cash forecast following a slower than expected cash burn in H1.

Companies: Sensyne Health
  • 11 Jul 19
Diversification and scale for online success

The global online gaming market generated c £40bn of gross gaming revenues (GGR) in 2018 and newly regulating markets (the US) are expected to contribute to 7% CAGR to 2023 (according to H2 Gambling Capital (H2GC)). However, while regulated markets have provided significant opportunities for operators to date, government intervention remains a constant threat and legislation is tightening. Some mature markets (notably the UK) have been raising taxes and implementing regulatory burdens, which increases the cost of business. In our view, success will depend on a combination of scale, diversification, proprietary technology and a strong balance sheet. Many of the 12 operators in this report should benefit from these dynamics and sector valuations remain attractive, at 12.6x P/E, 8.2x EV/EBITDA and 6.0% dividend yield for FY19.

Companies: 888 ACX BETSB ORPH GVC GYS OPAP PTEC RNK WMH

  • 04 Nov 19
Solid Q3 results in second EPS guidance upgrade for the year

Sales momentum accelerated in Q3 19 driven by the robust performance in the vaccines segment, particularly the shingles drug. The pharma (led by respiratory and immunology franchise) and consumer healthcare segments also performed well. The solid top-line was enough to absorb the higher R&D and SG&A expenses, and was further helped by lower tax and finance costs to facilitate the second EPS guidance upgrade for the year.

Companies: GlaxoSmithKline
  • 26 Nov 19
MaxCyte - Pole Position in Cell and Gene Therapy

MaxCyte Inc (LON:MXCT) is well-positioned to leverage its proprietary flow electroporation technology that is driving innovation, not only for its differentiated cell therapy platform CARMA but for a fast-growing list of leading industry partners. MXCT has more than 80 licensed programmes including

Companies: MaxCyte
  • 04 Dec 19
Cenkos: IXICO Plc -- Revenues growing and profitable

IXICO has reported a strong financial performance for FY19A built on continued commercial focus and a strengthened organisation. Revenues of £7.6m were up 40% and gross margin was up 600bps versus FY18A and the company delivered its first year of profitability since IPO. EBITDA of £0.5m was strongly ahead of our forecast (+£0.1m) and delivered an EBITDA margin of 6%. We have maintained our revenue growth expectations of 20% for FY20E and FY21E but have upgraded our profit expectations given the strong reported performance. We maintain our Buy recommendation.

Companies: IXICO
  • 09 Dec 19
ImmuPharma Quick Reference Sheet following new Lupuzor licence

Following the recent announcement that Avion Pharmaceuticals has entered into a licence to pay up to $25m to develop (through the second phase III trial) and commercialise its major drug Lupuzor ™, ImmuPharma presents a very different opportunity compared to even a few weeks ago.

Companies: ImmuPharma
  • 24 Dec 19
SP Angel Healthcare Conditions

Beximco Pharma (BXP.L): Annual General Meeting Statement | Polarean Imaging (POLX.L): Installation of research unit

Companies: Beximco Pharmaceuticals Polarean Imaging

  • 08 Jan 20
LIBERUM: Sensyne Health* - Major operational progress unjustly overlooked

Since foundation in mid-2018 Sensyne has signed deals with 5 NHS trusts to give it access to some of the best healthcare data globally. This has been validated by a deal with Bayer in its most important therapeutic area, with Cognizant in a field within which it is a global leader and with Roche to provide services the bears would suggest it already has in-house.

Companies: Sensyne Health
  • 14 Jan 20
Taking on China

Shield Therapeutics (STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Recent news that the FDA had approved this drug for a broad indication opened up a market in the US currently worth over $1bn p.a. On 8 January, STX announced a development and commercialisation licence deal in China with Beijing Aosaikang Pharmaceutical Co (ASK Pharm), whose local expertise should support approval and deliver strong licensing income in what is the world’s second largest pharmaceuticals market.

Companies: Shield Therapeutics
  • 17 Jan 20
Nigerian approval of VISITECT

Omega announced that the Nigerian Ministry of Health has approved its VISITECT CD4 350 diagnostic test, thereby paving the way for first shipments to its distributor, which has already placed orders for 250k tests with a value of c.£1.0m. Pending confirmation of actual delivery dates, our forecasts assume c.£0.5m is booked in the current financial year, rising to c.£2m in FY 2021 as the expected approval of VISITECT CD4 under the WHO Pre-Qualification programme in 2020 will allow full procurement of the VISITECT CD4 Advanced Disease test by United Nations organisations. We leave our target price unchanged at 25p.

Companies: Omega Diagnostics Group
  • 11 Mar 16
AIM Journal

Major shareholder easyGroup has requisitioned a general meeting at Africafocused airline fastjet to unseat chief executive Ed Winter, who previously announced he would leave, but after a handover period following the appointment of his successor. easyGroup also wants to remove Krista Bates from the board because of concerns about fastjet’s cost base and its cash outflow. easyJet founder Sir Stelios Haji-Ioannou was employed as a consultant in 2011 to help to set up the airline. He was given an initial 5% stake and the right to subscribe for a further 10% of the company. On top of that he got a royalty of 0.5% of revenues for the use of fastjet.com over a ten-year period but this was terminated in return for the issue of £1.51m-worth of shares at the equivalent of 160p each, and an agreement to subscribe for £1m in a placing at the same price. Even after further share issues, he owns 12.6% of fastjet through easyGroup following a recent share purchase. fastjet has been successful in raising money but the share price has fallen sharply over the past three years from the equivalent of £28 after two share consolidations to 67.25p. Sir Stelios accuses Winter of burning through £80m of cash in three years and believes that the company will run out of cash later this year.

Companies: MTFB WHI GHE AGQ AMO SAT DOTD